ascopubs.org

Randomized study of darbepoetin alfa as modifier of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): Final outcome of the DAHANCA 10 ...

Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: Platinum-based CT plus cetuximab in first-line R/M SCCHN No significant financial relationships to disclose. This ...
FierceBiotech

PRESS RELEASE: Phase 2 Study Suggests That Extended Dosing of Aranesp is as Efficacious as Weekly Dosing

BARCELONA, Spain -- Sept. 26, 2007--Amgen today announced data from a Phase 2, randomized, multicenter, open-label study that suggest extended dosing of Aranesp(R) (darbepoetin alfa) paired with ...
ascopubs.org

Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia: Disease Progression and Survival Analysis From Four Randomized, Double-Blind, Placebo-Controlled Trials

Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women Two 16-week randomized, double-blind, placebo-controlled ...
News Medical

Test document

This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...
Nature

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

Patients with low or intermediate-1 (int-1) International Prognostic Scoring System (IPSS) risk myelodysplastic syndromes (MDS) have a median survival of 5.7 and 3.5 years, respectively, when treated ...